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ABSTRACT
Objectives To assess disease trends, testing practices, 
community surveillance, case- fatality and excess deaths 
in children as compared with adults during the first 
pandemic peak in England.
Setting England.
Participants Children with COVID-19 between January 
and May 2020.
Main outcome measures Trends in confirmed 
COVID-19 cases, severe acute respiratory syndrome 
coronavirus 2 (SARS- CoV-2) positivity rates in children 
compared with adults; community prevalence of SARS- 
CoV-2 in children with acute respiratory infection (ARI) 
compared with adults, case- fatality rate in children 
with confirmed COVID-19 and excess childhood deaths 
compared with the previous 5 years.
Results Children represented 1.1% (1,408/129,704) 
of SARS- CoV-2 positive cases between 16 January 2020 
and 3 May 2020. In total, 540 305 people were tested 
for SARS- COV-2 and 129,704 (24.0%) were positive. In 
children aged <16 years, 35,200 tests were performed 
and 1408 (4.0%) were positive for SARS- CoV-2, 
compared to 19.1%–34.9% adults. Childhood cases 
increased from mid- March and peaked on 11 April before 
declining. Among 2,961 individuals presenting with ARI 
in primary care, 351 were children and 10 (2.8%) were 
positive compared with 9.3%–45.5% in adults. Eight 
children died and four (case- fatality rate, 0.3%; 95% CI 
0.07% to 0.7%) were due to COVID-19. We found no 
evidence of excess mortality in children.
Conclusions Children accounted for a very small 
proportion of confirmed cases despite the large numbers 
of children tested. SARS- CoV-2 positivity was low even in 
children with ARI. Our findings provide further evidence 
against the role of children in infection and transmission 
of SARS- CoV-2.
INTRODUCTION
Experience from countries recovering from large 
outbreaks of COVID-19 shows that children rarely 
develop severe or critical illness,1 or die from the 
infection as compared with adults.2 3 It is still 
unclear why the epidemiology, clinical features and 
outcomes of COVID-19 are so different in children 
compared with adults. COVID-19, caused by the 
severe acute respiratory syndrome coronavirus 2 
(SARS- CoV-2), typically presents as an acute respi-
ratory illness. Common symptoms include fever 
and cough, as well as fatigue, chest tightness and 
dyspnoea, although individual symptoms or clusters 
of symptoms have moderate to low sensitivity and 
specificity for the infection.4 While most individuals 
recover without specific treatment or hospitalisa-
tion, some, especially older adults, may progress to 
acute respiratory distress syndrome and multiorgan 
failure, which is associated with high case- fatality 
rates despite early and aggressive management in 
intensive care settings.5 6
In England, with a population of 55 million 
individuals, the first imported cases of COVID-19 
were identified at the end of January 2020. Initially, 
case numbers increased slowly and were related to 
imported cases. However, despite contact tracing 
and testing individuals who met a geographic and 
symptom- based case definition, cases with no clear 
transmission chains or overseas travel started to 
emerge at the end of February. These cases were 
detected through community sentinel surveillance 
schemes, and cases without overseas travel were 
diagnosed in intensive care units (ICUs), through 
ICU sentinel surveillance, on the first week of 
March. Cases increased rapidly during the subse-
quent 2 weeks with evidence of community trans-
mission across the country.
What is already known on this topic?
 ► Children account for only a small proportion of 
confirmed cases of COVID-19.
 ► Most childhood cases of COVID-19 are mild and 
self- limiting.
 ► Whether this is due to limited testing for severe 
acute respiratory syndrome coronavirus 2 
(SARS- CoV-2) in children is not known.
What this study adds?
 ► Despite widespread testing, SARS- CoV-2 
positivity rates throughout the pandemic 
peak were low in children compared with 
adults, including those presenting with acute 
respiratory infection in the community.
 ► Case- fatality rate in children with COVID-19 
was <0.5% and there was no evidence of 
excess childhood mortality in children during 
the first wave of the COVID-19 pandemic in 
England.
 o
n
 August 20, 2020 by guest. Protected by copyright.
http://adc.bmj.com/
Arch D
is Child: first published as 10.1136/archdischild-2020-320042 on 12 August 2020. Downloaded from
 
2 Ladhani SN, et al. Arch Dis Child 2020;0:1–6. doi:10.1136/archdischild-2020-320042
Original research
On 12 March, the UK moved from a containment to a 
delay phase of the government response to the pandemic, with 
emphasis placed on slowing the spread of the virus, lowering the 
peak impact on hospital and ICU services and pushing it away 
from the winter season; this included the recommendation for 
anyone with fever or cough to stay at home. Available testing 
capacity from individuals with mild symptoms in the commu-
nity was also shifted to those who required hospitalisation and 
for outbreak investigations in closed institutional settings (such 
as care homes and prisons). On 23 March, the UK government 
closed all but essential shops and services and recommended that 
the entire population stayed at home unless they provided an 
essential service or were a key worker.
In England, Public Health England (PHE) has been conducting 
enhanced national surveillance of COVID-19 since the first cases 
were reported in Wuhan, China, in December 2019.7 While 
adults rightly remained the primary focus of national surveil-
lance, an extensive surveillance strategy was also established to 
contemporaneously monitor childhood COVID-19 in England.7
Currently, COVID-19 cases have peaked and hospital admis-
sions are the lowest since 23 March in England.8 Here, we 
describe the surveillance, epidemiology and outcomes of child-
hood COVID-19 during the first peak. In addition to disease 
trends, we assessed SARS- CoV-2 positivity rates in different 
childhood age groups compared with adults, community surveil-
lance of SARS- CoV-2 in children and adults presenting with 
acute respiratory infection in primary care, cause of death in 
SARS- CoV-2- positive children and monitoring excess deaths in 
children compared with the previous 5 years.
METHODS
PHE initiated COVID-19 surveillance in England after the first 
cluster of cases was reported in Wuhan, Hubei Province, China 
in December 2019. In early January, an RT- PCR diagnostic test 
for SARS- CoV-2 was developed and validated by PHE. By early 
March 2020, the tests were also delivered by PHE regional labo-
ratories and National Health Service (NHS) laboratories across 
England. Case definitions for SARS- CoV-2 testing varied over the 
course of the first peak of the pandemic (table 1).9 Throughout 
this period, confirmed cases and their close contacts were isolated 
to prevent transmission into the community. During the delayed 
phase of outbreak control, emphasis was shifted to testing those 
presenting to hospital with suspected COVID-19 with the aim 
of rapidly diagnosing cases and protecting those who were 
SARS- CoV-2 negative. Clinical follow- up of confirmed cases in 
children aged <16 years began at the start of the pandemic and 
is ongoing.7 Fatal cases were identified through regular linkage 
with the Patient Demographic Service, an electronic database of 
all NHS patients, as well as direct reporting of deaths by paedia-
tricians and local Health Protection Teams.
SARS-COV-2 POSITIVITY
The respiratory DataMart system and Second Generation Surveil-
lance System (SGSS) were used to assess SARS- CoV-2 testing 
in different age groups.10 SGSS receives reports of all positive 
SARS- CoV-2 tests, as part of its laboratory data capture. In addi-
tion, the previous DataMart system and SGSS were modified to 
include negative results from NHS and Public Health laborato-
ries, which were then consolidated in a unified database which 
used a probabilistic algorithm to remove duplicates and results 
from patients that had tested positive. Positive results from one 
laboratory that only reported positives and results from patients 
outside England were excluded.
COMMUNITY SWABBING
Community- based surveillance for influenza- like illness was 
established by the Royal College of General Practitioners 
Research and Surveillance Centre creating a network of general 
practices across England and Wales >50 years ago.11 12 Adults 
and children presenting to around 100 participating general 
practices with an influenza- like illness (defined as fever with 
one systemic and one respiratory symptom) had a nasopharyn-
geal swab taken for testing. Clinicians were instructed to sample 
one or two patients a week. Details of the swabbing scheme 
are detailed elsewhere.11 In March 2020, this surveillance was 
extended for SARS- CoV-2 testing in the community, including 
expanding the number of virology sampling practices to 300.11
Table 1 Summary of case definitions for population testing for 
SARS- CoV-2 in England
Time period Case definition
Before 7 February 2020 Epidemiological criteria
In the 14 days before the onset of illness:
 ► travel to China OR contact with a confirmed case of 
COVID-19;
and Clinical criteria
 ► severe acute respiratory infection requiring admission 
to hospital with clinical or radiological evidence of 
pneumonia or acute respiratory distress syndrome;
OR
 ► acute respiratory infection of any degree of severity, 
including at least one of shortness of breath (difficult 
breathing in children) or cough (with or without fever);
OR
 ► fever with no other symptoms.
From 7 February 2020 Epidemiological criteria
In the 14 days before the onset of illness:
 ► travel to affected countries, including transit, for any 
length of time, in these countries OR contact with a 
confirmed case of COVID-19;
and Clinical criteria
 ► severe acute respiratory infection requiring admission 
to hospital with clinical or radiological evidence of 
pneumonia or acute respiratory distress syndrome;
OR
 ► acute respiratory infection of any degree of severity, 
including at least one of shortness of breath (difficult 
breathing in children) or cough (with or without fever);
OR
 ► fever with no other symptoms.
From 13 March 2020 Inpatient definition
 ► requiring admission to hospital;
and
 ► have either clinical or radiological evidence of 
pneumonia;
OR
 ► acute respiratory distress syndrome;
OR
 ► influenza- like illness (fever ≥37.8°C and at least one 
of the following respiratory symptoms, which must 
be of acute onset: persistent cough (with or without 
sputum), hoarseness, nasal discharge or congestion, 
shortness of breath, sore throat, wheezing or sneezing.
*Imported cases were defined as cases with travel to countries with known 
COVID-19 circulation at the time or with contact with a confirmed case while 
abroad within a maximum incubation period of their onset of symptoms.
†Secondary cases were defined as cases that had contact with a confirmed or 
probable/suspected case in the UK and did not fit the definition of an imported 
case.
‡Sporadic cases were defined as cases with no travel history to countries with 
known COVID-19 circulation, and no known contact with a confirmed case.
SARS- CoV-2, severe acute respiratory syndrome coronavirus 2.
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MORTALITY TRENDS
Data on death registrations until midnight on each day are sent 
the next day to PHE by the General Registry Office. Death regis-
trations since 1 January 2015 were aggregated by age in years, 
date of death, date of registration, gender and region. To model 
weekly all- cause deaths by week of death in children, the Euro-
momo algorithm was used to fit a trend to deaths in the past 
5 years using only spring and autumn data (to avoid potential 
spikes from influenza and cold weather). The data were modelled 
using a Poisson distribution with rescaling based on overdisper-
sion and an expected number calculated along with predictions 
limits (+2 Z- scores). To account for delays from death to regis-
tration, which could be long if reported to a coroner, an adjust-
ment to data from the previous 50 weeks was applied using a 
model of the proportion of deaths registered with each time lag 
from 0 to 50 weeks. The same model is used to estimate excess 
mortality in older age groups with the exception that a cosine 
wave is used to capture the usual pattern of higher deaths in 
the winter compared with summer. Results of excess mortality 
trends are reported to Euromomo each week and presented as a 
Z- score analysis (https://www. euromomo. eu/).13
RESULTS
EPIDEMIOLOGY
Between 1 January and 3 May 2020, 129 704 (24.0%) out of 
540 305 people tested positive for SARS- CoV-2 in England. In 
children, the first confirmed cases were reported on 29 February 
2020. Cases started to increase during the second week of March 
and peaked on 11 April 2020 before declining gradually, corre-
sponding to the trends observed in adults (figure 1). COVID-19 
cases were confirmed across the country, with greater numbers 
diagnosed in large cities (figure 2). Children accounted for 1408 
(1.1%) confirmed cases across all age groups and 742 (52.7%) 
were male. The median age of childhood cases was 5.9 years, 
with higher number of cases in infants and older adults (figure 3).
Test positivity rates by age
Children represented 6.6% (n=35 200) of 536 278 people with 
reported age who were tested for SARS- CoV2 and 1408/35 200 
(4.0%) children tested were positive, compared with 19.1%–
34.9% of adults (figure 4). Infants aged <3 months (272/4072), 
followed by older infants (128/3358) and children aged 1 year 
(107/4280) had the most tests performed and the highest number 
of positive tests among children aged <16 years (figure 1). Test- 
positivity rates varied over the course of the pandemic, peaking 
around the same time as the peak in COVID-19 cases (figure 1).
Community surveillance of acute respiratory infection
Overall, 2968 individuals with influenza- like illness presenting 
to any of the participating general practices had nasopharyn-
geal swabs taken and 10 (2.8%) of 351 children were positive 
compared with 9.3% (88/946) in those aged 15–44 years, 18.6% 
Figure 1 Epidemic curve (A), cumulative number of confirmed cases 
(B) and proportion of test positives (C) by age group for COVID-19 
in children during the first pandemic peak (February to May 2020) in 
England.
Figure 2 Distribution of confirmed COVID-19 cases in children during 
the first pandemic peak (February to May 2020) in England.
Figure 3 Age distribution of children with confirmed COVID-19 by sex 
in children during the first pandemic peak (February to May 2020) in 
England.
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(178/959) in those aged 45–64 years, 20.6% (74/359) in those 
aged 65–79 years and 45.5% (150/330) in adults aged ≥80 
years (figure 5). Samples were taken throughout the surveillance 
period and children rarely tested positive at any time, especially 
those aged 3–9 years, where only 1 of 168 (0.6%) was positive.
Deaths
There were eight deaths in children with confirmed COVID-19. 
Four children aged 10–15 years, three of whom had multiple 
comorbidities, died (CFR, 0.3%; 95% CI 0.07% to 0.7%) of the 
infection. In the remaining cases, another cause was identified 
and SARS- CoV-2 was reported to be incidental or an indirect 
contributor to death.
Mortality surveillance
There has been no increase in excess deaths in children aged 
0–15 years until 3 May 2020 (figure 6). Between weeks 12 and 
18 of 2020, where excess deaths have been reported in other 
age groups, the cumulative number of corrected daily deaths in 
children was one fewer than the expected number for this period 
when compared to the same period in the pre- COVID-19 era.
DISCUSSION
The experience in England adds to the growing body of evidence 
on the limited role of children in the COVID-19 pandemic, with 
just over 1% of confirmed cases occurring in children. Infants, 
especially those children aged <3 months and those aged 1 year 
were the most tested age groups and had the highest number 
of positive cases. With nearly half a million SARS- CoV-2 tests 
performed during the first 4 months of 2020, the positivity rate 
among 35 200 children tested was only 4.0% compared with 
19.1%–34.9% in adults and older adults. Community testing of 
children presenting in primary care with acute respiratory infec-
tion identified very low rates of SARS- CoV-2 positivity (2.8%) 
even at the peak of the pandemic, especially among preschool 
and primary school- aged children. This contrasts with the higher 
positivity rates with increasing age in adults, reaching nearly 
50% in those aged ≥80 years. Currently, SARS- CoV-2 posi-
tivity rates in the community are low across all age groups.14 
Reassuringly, the case- fatality rate in children was below 0.5% 
with no evidence of excess mortality during the first peak of the 
COVID-19 pandemic in England.
Other countries with widespread SARS- CoV-2 testing prac-
tices have all reported low COVID-19 rates in children, who 
accounted for only 1%–3% of total confirmed cases.3 Inclusion 
of negative test results provides further reassurance of the large 
numbers of tests performed across all age groups, including chil-
dren. The lower risk of COVID-19 may be due to lower expres-
sion of the cell surface enzyme ACE2 in the nasal epithelium of 
children compared with adults.15 This binds to the SARS- CoV-2 
spike protein and promotes internalisation of the virus into 
human cells. Although clinical follow- up of childhood cases is 
ongoing, our initial assessment based on the source of paedi-
atric testing suggests that around half the confirmed cases were 
hospitalised, which compares with 33% in the USA and 67% in 
Italy.16 17 Those that were not hospitalised were mainly during 
the containment phase when close contacts of confirmed cases, 
Figure 4 Percentage of test positivity by age group in children (green 
bar) compared with adults (blue bars) tested for severe acute respiratory 
syndrome coronavirus 2 during the first pandemic peak (February to 
May 2020) in England.
Figure 5 Number of children with acute respiratory infection who 
were tested for severe acute respiratory syndrome coronavirus 2 
(SARS- CoV-2) in general practices across England over the course of 
the pandemic (A) and by age (B). Figure 3C depicts the proportion of 
individuals with acute respiratory infection who tested positive by age 
and sex in England.
Figure 6 Observed, delay- corrected and expected all- cause deaths 
in children aged 0–15 years in England from 2015 (week 40) to 2020 
(week 18). Data are shown by week of death.
 o
n
 August 20, 2020 by guest. Protected by copyright.
http://adc.bmj.com/
Arch D
is Child: first published as 10.1136/archdischild-2020-320042 on 12 August 2020. Downloaded from
 
5Ladhani SN, et al. Arch Dis Child 2020;0:1–6. doi:10.1136/archdischild-2020-320042
Original research
specifically children of key workers, were screened for the virus, 
along with children attending the emergency department with 
acute respiratory infections.
A key unanswered question remains whether asymptomatic 
children might be contributing to community transmission of 
SARS- CoV-2. Reports of asymptomatic carriage in children are 
mainly from active follow- up of contacts of confirmed cases or 
screening children without adequate follow- up to determine 
whether they were presymptomatic or truly asymptomatic,18 as 
has been reported in adults.19 Although community testing of 
SARS- CoV-2 in England was not as widespread as some other 
countries, especially during the peak of the pandemic, our data 
found that only 4.0% of children nationally and only 2.8% of 
symptomatic children with acute respiratory infection in the 
community tested positive for SARS- CoV-2.
In Iceland, only 38/564 (6.7%) children aged <10 years who 
were symptomatic, had recently travelled to high- risk countries 
or had contact with infected persons, were positive compared 
with 1183/8635 (13.7%) individuals aged ≥10 years.20 The 
difference was more marked in population screening during 
lockdown when daycare and elementary schools remained open, 
yet none of 848 children aged <10 years were positive compared 
with 100/12 232 (0.8%) in children aged ≥10 years.21 In the 
Netherlands, community testing of patients presenting with 
acute respiratory infection in primary care also did not iden-
tify SARS- CoV-2- positive children.22 Additionally, children were 
never the first to be infected or to be the source of infection in 
the household.22 This is supported by other household transmis-
sion studies where children of confirmed cases, especially those 
aged <10 years, were significantly less likely to be SARS- CoV-2 
positive or becoming symptomatic when compared with adults 
in the same household.23 24 This also applies in educational 
settings. In New South Wales, Australia, 9 students and 9 staff 
from 15 schools had confirmed COVID-19 and 735 students 
and 128 staff were identified as close contacts.25 No teacher or 
staff member, and only one child from a primary school and one 
child from a high school, may have contracted COVID-19 from 
the initial school cases.25
An unintended consequence of the COVID-19 lockdown on 
children has been that the national ‘Stay at Home’ message, along 
with concerns about acquiring COVID-19 in hospital, discour-
aged parents from seeking medical help, resulting in large reduc-
tions in emergency department attendances and hospitalisation 
than in previous years.26 27 This has led to significant concerns 
about delayed presentations and potentially avoidable fatali-
ties.17 Reassuringly however, we were unable to identify any 
overall excess childhood mortality in England. This contrasts 
with adult data using the same methodology where high levels of 
excess mortality were observed in all but the age group of 0–14 
years, and especially among those aged ≥85 years. In England 
alone, there were an estimated 56 456 all- cause excess deaths 
during the 2 months since 16 March 2020.28
Finally, the very low childhood case- fatality rate is reassuring 
and consistent with the global literature.1 In England, regular 
prospective data linkage using multiple sources allowed rapid 
capture and follow- up of fatal cases. Recently, however, a small 
number of children in England presented with hyperinflam-
matory shock and mixed features of atypical Kawasaki disease 
and toxic shock syndrome; these children progressed to warm, 
vasoplegic shock, requiring volume resuscitation and inotropic 
support.29 Since then, similar cases with varying presentations 
and severities have been reported in other countries that have 
experienced the COVID-19 pandemic.30 Investigations are 
ongoing to assess the temporal association with SARS- CoV-2.
Strengths and limitations
The strength of this study is the establishment of a single national 
surveillance hub with access to multiple local and national data 
sources in near real- time. The availability of total tests performed 
was critical to assess any effects of test shortages and changes in 
testing recommendations. The data also provided insight into 
the age distribution of confirmed COVID-19 cases; the large 
numbers of tests performed in infants aged <3 months suggested 
wider testing, potentially including those born to SARS- CoV-
2- positive pregnant women. The outcomes of SARS- COV-2- 
positive neonates and of infants born to SARS- CoV-2 mothers 
are being assessed in a national prospective study currently 
underway in the UK and Ireland.7 Similarly, the large number 
of tests and positive results in older infants and children aged 
1 year is likely to reflect wider testing for SARS- CoV-2 in these 
age group because of frequent presentations with non- specific 
febrile illnesses. Collecting data across the age groups allowed 
comparison of children with adults for test positivity overall 
and in community surveillance of acute respiratory infections 
in primary care. Limitations include the suboptimal sensitivity 
of nasopharyngeal and oropharyngeal swabs for SARS- CoV-2.31 
The lack of reliable serology during the pandemic also meant 
that cases could not be confirmed retrospectively. Important 
questions still remain unanswered. We need more information 
on asymptomatic childhood SARS- CoV-2 infection and trans-
mission as well as seroincidence studies in community and 
educational settings. Such studies are underway (https://www. 
gov. uk/ guidance/ covid- 19- paediatric- surveillance) and will 
become particularly important to ease the lockdown and allow 
children and teachers safely back to school, and to understand 
transmission patterns should a second peak emerge.
CONCLUSIONS
England is currently nearing the end of the first peak of the 
COVID-19 pandemic. Consistent with other countries, children 
account for a very small proportion of confirmed cases and have 
very low case- fatality rates. Despite the large number of children 
tested, only 4% were positive for SARS- CoV-2. In the commu-
nity, SARS- CoV-2 positivity was low even in children presenting 
with acute respiratory infections. Community transmission and 
serosurveillance will become increasingly important as lock-
down measures are gradually eased.
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